HNB
ALNY icon

Hilltop National Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hilltop National Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-131
Closed -$43.3K – 808
2026
Q1 		$43.3K Buy
131
+51
+64% +$17.4K 0.01% 495
2025
Q4 		$31.8K Sell
80
-11
-12% -$4.87K 0.01% 526
2025
Q3 		$41.5K Buy
+91
New +$37.1K 0.01% 481

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Hilltop National Bank's ALNY Position: Q2 2026 in Review

Hilltop National Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 131 shares — an estimated $43.3K sold.

Hilltop National Bank first reported a position in ALNY in Q3 2025 and held it in 3 quarters. The position peaked at $43.3K in Q1 2026. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Hilltop National Bank reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hilltop National Bank sold 131 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $43.3K.
  • Hilltop National Bank first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Hilltop National Bank's Alnylam Pharmaceuticals position peaked at $43.3K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Hilltop National Bank's 13F filing for Q2 2026, filed 2 Jul 2026.